Pfizer

Diversified pharma

PFE · NYSE · United States

Share price · PFE

$28.06+0.81 (+2.97%) 3M

close as of 2026-11-18 · 24h delayed · vol 37.7M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PFE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026-2.2%
  2. 5 Oct 2026-1.4%
  3. 24 Jul 2026-1.9%
  4. 24 Jun 2026-2.8%
  5. 7 Apr 2026-2.6%
  6. 17 Mar 2026+3.2%
  7. 6 Mar 2026+1.7%
  8. 10 Feb 2026+2.1%
  9. 4 Feb 2026+3.9%
  10. 3 Feb 2026-3.3%

Share of unusual movement by asset

For each asset, the share of PFE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack) (Avmapki Fakzynja Co-Pack)
events and moves
86%
Enfortumab Vedotin
events and moves
183%
Disitamab Vedotin
events and moves
91%
brepocitinib (Lisraya)
events and moves
6shown from 8 days
Vepdegestrant (Veppanu)
events and moves
6shown from 8 days
etrasimod (Velsipity)
events and moves
3shown from 8 days
ecnoglutide
events and moves
3shown from 8 days
Reboxetine
events and moves
3shown from 8 days
Elranatamab
events and moves
2shown from 8 days
tilrekimig
events and moves
2shown from 8 days
Sasanlimab
events and moves
2shown from 8 days
infliximab-dyyb (Inflectra) (Inflectra)
events and moves
2shown from 8 days
Esreboxetine
events and moves
2shown from 8 days
Berobenatide
events and moves
1shown from 8 days
tofacitinib (Xeljanz)
events and moves
1shown from 8 days
Encorafenib
events and moves
1shown from 8 days
PF-06651600
events and moves
1shown from 8 days
ompekimig
events and moves
1shown from 8 days
Atirmociclib
events and moves
1shown from 8 days
Crizotinib
events and moves
1shown from 8 days
Tucatinib
events and moves
1shown from 8 days
Talazoparib
events and moves
1shown from 8 days
Palbociclib (Ibrance)
events and moves
1shown from 8 days
Brentuximab Vedotin
events and moves
1shown from 8 days
Sugemalimab (Cejemly)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—11%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—63%

Assets

(95 total)
95Total Assets
43Approved
18Phase 3 / Filed
34Phase 1–2 / Early
65Diseases
Quick filter:
Showing 95 of 95 assets
Target & Modality
abrocitinib(Cibinqo)
Approved
JAK1Small molecule
Atopic Dermatitis
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
MEK1/2 and RAF (CRAF, BRAF) · FAKSmall molecule
Ovarian Cancer
Approved
VEGFR1/2/3Small molecule
Renal Cell Carcinoma
Approved
MEK1/2Small molecule
Non-Small Cell Lung CancerMelanoma
Approved
Anti-CD30 antibody-drug conjugateAntibody–drug conjugate
Non-Small Cell Lung CancerDiffuse Large B-Cell LymphomaNon-Hodgkin LymphomaCutaneous T-Cell Lymphoma
Large B-Cell Lymphoma, Peripheral T-Cell Lymphoma, High-Grade B-Cell Lymphoma
brepocitinib(Lisraya)
Approved
TYK2/JAK1Small molecule
PsoriasisDermatomyositisNon-Infectious UveitisCutaneous SarcoidosisLichen PlanopilarisIdiopathic Inflammatory Myopathies
crisaborole(Eucrisa)
Approved
PDE4Small molecule
Atopic Dermatitis
Approved
ALK, ROS1, MET/HGFR, and RONSmall molecule
Non-Small Cell Lung Cancer
Approved
EGFR/HER1, HER2, HER4Small molecule
Non-Small Cell Lung Cancer
Approved
BCMA x CD3Multispecific antibody
Multiple Myeloma
Approved
BRAF V600ESmall molecule
Non-Small Cell Lung CancerColorectal CancerMelanoma
Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer
Approved
Nectin-4Antibody–drug conjugate
Non-Small Cell Lung CancerBladder Cancer
Approved
Topoisomerase II / DNASmall molecule
Breast Cancer
Ertugliflozin(Steglatro)
Approved
SGLT2Small molecule
Type 2 Diabetes

Upcoming events

(125 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (12)
November 2026 (1)
Rimegepant (Nurtec ODT)Phase 3Menstrual Migraine
Est. primary completion 2026-11-29 · NCT06641466 · CT.gov ↗
What to watch
December 2026 (11)
Disitamab VedotinPhase 2/3Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
PF-06651600Phase 3Severe Alopecia Areata
Est. primary completion 2026-12-02 · NCT07029711 · CT.gov ↗
What to watch
PF-07307405Phase 3Lyme Disease
Est. primary completion 2026-12-04 · NCT07500506 · CT.gov ↗
What to watch
PF-06651600Phase 2Hidradenitis Suppurativa
Est. primary completion 2026-12-08 · NCT07228390 · CT.gov ↗
What to watch
Disitamab VedotinPhase 2Urothelial Carcinoma
Est. primary completion 2026-12-11 · NCT04879329 · CT.gov ↗
What to watch
PF-06651600Phase 2Chronic Spontaneous Urticaria
Est. primary completion 2026-12-25 · NCT07219615 · CT.gov ↗
What to watch
Est. primary completion 2026-12-30 · NCT05909397 · CT.gov ↗
What to watch
afimkibartPhase 2Crohns Disease
Est. primary completion 2026-12-31 · NCT05910528 · CT.gov ↗
What to watch
Palbociclib · Ibrance + TegtociclibPhase 2Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Est. primary completion 2026-12-31 · NCT04553133 · CT.gov ↗
What to watch
Lorlatinib + Axitinib + TalazoparibPhase 3Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer, Solid Tumors
Est. primary completion 2026-12-31 · NCT05059522 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Urothelial Carcinoma, HER2-expressing
Est. primary completion 2026-12-31 · NCT05302284 · CT.gov ↗
What to watch
2027 (36)
January 2027 (2)
Disitamab VedotinPhase 3Urothelial Carcinoma
Est. primary completion 2027-01-29 · NCT05911295 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2027-01-30 · NCT06589986 · CT.gov ↗
What to watch
February 2027 (4)
2026-12-31 Financial ReportEarnings report
Expected report date 2027-02-02 · Fiscal period ending 2026-12-31
What to watch
Atirmociclib + TegtociclibPhase 1/2Breast Cancer, Solid Tumors
Est. primary completion 2027-02-26 · NCT05262400 · CT.gov ↗
What to watch
ecnoglutidePhase 2Obesity, Weight Management
Est. primary completion 2027-02-27 · NCT07073417 · CT.gov ↗
What to watch
MevrometostatPhase 3Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Est. primary completion 2027-02-28 · NCT06551324 · CT.gov ↗
What to watch
March 2027 (5)
tilrekimigPhase 2Asthma
Est. primary completion 2027-03-08 · NCT06977581 · CT.gov ↗
What to watch
tofacitinib · XeljanzPhase 3Ulcerative Colitis
Est. primary completion 2027-03-17 · NCT04624230 · CT.gov ↗
What to watch
Vepdegestrant · VeppanuPhase 1/2Breast Cancer
Est. primary completion 2027-03-24 · NCT05548127 · CT.gov ↗
What to watch
Binimetinib + EncorafenibPhase 3Melanoma
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
PF-06651600Phase 3Vitiligo
Est. primary completion 2027-03-31 · NCT06163326 · CT.gov ↗
What to watch
April 2027 (2)
afimkibartPhase 2Rheumatoid Arthritis
Est. primary completion 2027-04-17 · NCT07137598 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3Iron Deficiency, Anaemia in Children
Est. primary completion 2027-04-30 · NCT05179226 · CT.gov ↗
What to watch
May 2027 (1)
Est. primary completion 2027-05-02 · NCT06807268 · CT.gov ↗
What to watch
June 2027 (1)
Disitamab VedotinPhase 2Cervical Cancer
Est. primary completion 2027-06-30 · NCT06155396 · CT.gov ↗
What to watch
July 2027 (2)
Exemestane + PrifetrastatPhase 3Breast Cancer
Est. primary completion 2027-07-22 · NCT07062965 · CT.gov ↗
What to watch
PF-06651600Phase 3Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Est. primary completion 2027-07-30 · NCT06072183 · CT.gov ↗
What to watch
August 2027 (3)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 2Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
Est. primary completion 2027-08-01 · NCT07747506 · CT.gov ↗
What to watch
Berobenatide + MET-233iPhase 2Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity, Overnutrition, Nutrition Disorders …
Est. primary completion 2027-08-04 · NCT07575932 · CT.gov ↗
What to watch
ElranatamabPhase 3Multiple Myeloma
Est. primary completion 2027-08-04 · NCT05317416 · CT.gov ↗
What to watch
September 2027 (4)
ecnoglutidePhase 2Overweight , Obesity, Weight Management
Est. primary completion 2027-09-03 · NCT07929298 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity and Overweight
Est. primary completion 2027-09-21 · NCT07311850 · CT.gov ↗
What to watch
IbuzatrelvirPhase 3COVID-19 Infection
Est. primary completion 2027-09-28 · NCT07013474 · CT.gov ↗
What to watch
MevrometostatPhase 3Metastatic Castration-Resistant Prostate Cancer
Est. primary completion 2027-09-30 · NCT06629779 · CT.gov ↗
What to watch
October 2027 (4)
IbuzatrelvirPhase 3COVID-19 SARS-CoV-2 Infection
Est. primary completion 2027-10-01 · NCT06679140 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2, Type 2 Diabetes
Est. primary completion 2027-10-12 · NCT07400653 · CT.gov ↗
What to watch
PF-08634404Phase 1/2Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Liver Neoplasms …
Est. primary completion 2027-10-18 · NCT07227012 · CT.gov ↗
What to watch
Disitamab VedotinPhase 1/2Breast Cancer, Breast Neoplasms
Est. primary completion 2027-10-25 · NCT06966453 · CT.gov ↗
What to watch
November 2027 (2)
PF-08634404 + AxitinibPhase 1/2Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma …
Est. primary completion 2027-11-02 · NCT07227415 · CT.gov ↗
What to watch
Enfortumab VedotinPhase 2Muscle-invasive Bladder Cancer
Est. primary completion 2027-11-30 · NCT07475806 · CT.gov ↗
What to watch
December 2027 (6)
Disitamab VedotinPhase 1/2Non-small Cell Lung Cancer
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Ferric derisomaltose · Monoferric / MonoferPhase 3Chronic Heart Failure, Iron Deficiencies
Est. primary completion 2027-12-01 · NCT06929806 · CT.gov ↗
What to watch
ecnoglutidePhase 3OSA - Obstructive Sleep Apnea, Obesity
Est. primary completion 2027-12-16 · NCT07387094 · CT.gov ↗
What to watch
PF-08634404 + Enfortumab VedotinPhase 1/2Urothelial Cancer, Advanced/Metastatic Urothelial Cancer, Urothelial Carcinoma
Est. primary completion 2027-12-28 · NCT07421700 · CT.gov ↗
What to watch
TucatinibPhase 3Colorectal Neoplasms
Est. primary completion 2027-12-31 · NCT05253651 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Breast Cancer
Est. primary completion 2027-12-31 · NCT04400695 · CT.gov ↗
What to watch
2028 (35)
January 2028 (2)
PonsegromabPhase 2/3Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-01-23 · NCT06989437 · CT.gov ↗
What to watch
PF-07307405Phase 3Lyme Borreliosis
Est. primary completion 2028-01-27 · NCT07226882 · CT.gov ↗
What to watch
February 2028 (3)
EmraclidinePhase 2Schizophrenia
Est. primary completion 2028-02 · NCT07145918 · CT.gov ↗
What to watch
PF-08049820Phase 2Atopic Dermatitis, Eczema, Atopic
Est. primary completion 2028-02-02 · NCT07216027 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
Est. primary completion 2028-02-16 · NCT07845500 · CT.gov ↗
What to watch
March 2028 (6)
EsreboxetinePhase 3Fibromyalgia
Est. primary completion 2028-03 · NCT07398417 · CT.gov ↗
What to watch
tilrekimigPhase 3Atopic Dermatitis
Est. primary completion 2028-03-10 · NCT07765888 · CT.gov ↗
What to watch
Fetrastobart vedotinPhase 3Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Est. primary completion 2028-03-10 · NCT07144280 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight
Est. primary completion 2028-03-14 · NCT07792954 · CT.gov ↗
What to watch
PF-06651600Phase 3Alopecia Areata
Est. primary completion 2028-03-19 · NCT06873945 · CT.gov ↗
What to watch
PF-08634404Phase 2Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Small Cell Lung …
Est. primary completion 2028-03-24 · NCT07476287 · CT.gov ↗
What to watch
April 2028 (2)
PF-06651600Phase 3Alopecia Areata
Est. primary completion 2028-04-26 · NCT07733765 · CT.gov ↗
What to watch
BerobenatidePhase 3Apnea, Sleep Disorders, Overweight and/or Obesity
Est. primary completion 2028-04-30 · NCT07823608 · CT.gov ↗
What to watch
May 2028 (6)
EsreboxetinePhase 3Fibromyalgia
Est. primary completion 2028-05 · NCT07637162 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight and/or Obesity, Overweight
Est. primary completion 2028-05-04 · NCT07595549 · CT.gov ↗
What to watch
PF-07328948Phase 2Heart Failure
Est. primary completion 2028-05-08 · NCT06991257 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Gastric Carcinoma
Est. primary completion 2028-05-15 · NCT06944496 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2028-05-31 · NCT07846683 · CT.gov ↗
What to watch
ecnoglutidePhase 3Knee Osteoarthritis, Obesity
Est. primary completion 2028-05-31 · NCT07734311 · CT.gov ↗
What to watch
June 2028 (4)
BerobenatidePhase 3Apnea, Sleep Disorders, Overweight and/or Obesity
Est. primary completion 2028-06-01 · NCT07881757 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight
Est. primary completion 2028-06-06 · NCT07874633 · CT.gov ↗
What to watch
ecnoglutidePhase 3Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
Est. primary completion 2028-06-08 · NCT07836270 · CT.gov ↗
What to watch
ecnoglutidePhase 3OSA - Obstructive Sleep Apnea, Obesity
Est. primary completion 2028-06-19 · NCT07434050 · CT.gov ↗
What to watch
July 2028 (1)
PF-08634404Phase 2Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease …
Est. primary completion 2028-07-29 · NCT07489066 · CT.gov ↗
What to watch
August 2028 (2)
BerobenatidePhase 3Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2
Est. primary completion 2028-08-21 · NCT07915609 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity, Overweight, Osteoarthritis of the Knee
Est. primary completion 2028-08-22 · NCT07919678 · CT.gov ↗
What to watch
September 2028 (3)
MS-553Phase 1/2CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
Est. primary completion 2028-09 · NCT06979076 · CT.gov ↗
What to watch
tilrekimigPhase 3Atopic Dermatitis
Est. primary completion 2028-09-08 · NCT07783425 · CT.gov ↗
What to watch
MevrometostatPhase 3Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Est. primary completion 2028-09-12 · NCT07028853 · CT.gov ↗
What to watch
October 2028 (3)
BerobenatidePhase 3Urinary Incontinence, Stress, Overweight and/or Obesity
Est. primary completion 2028-10-13 · NCT07932925 · CT.gov ↗
What to watch
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 3Low Grade Serous Ovarian Cancer
Est. primary completion 2028-10-15 · NCT06072781 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT)Phase 3Preventive Treatment of Migraine
Est. primary completion 2028-10-21 · NCT07729462 · CT.gov ↗
What to watch
December 2028 (3)
Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)Phase 1/2Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2028-12-31 · NCT06819878 · CT.gov ↗
What to watch
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2028-12-31 · NCT06819891 · CT.gov ↗
What to watch
2029 (22)
January 2029 (2)
AtirmociclibPhase 3Breast Cancer
Est. primary completion 2029-01-02 · NCT06760637 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT)Phase 3Pediatric Migraine
Est. primary completion 2029-01-09 · NCT04649242 · CT.gov ↗
What to watch
February 2029 (2)
BerobenatidePhase 3Obesity
Est. primary completion 2029-02-21 · NCT07794774 · CT.gov ↗
What to watch
PF-08634404Phase 3Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) …
Est. primary completion 2029-02-27 · NCT07222566 · CT.gov ↗
What to watch
March 2029 (4)
PF-08634404 + Fetrastobart vedotinPhase 1/2Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Est. primary completion 2029-03-08 · NCT07227298 · CT.gov ↗
What to watch
BerobenatidePhase 3Obesity
Est. primary completion 2029-03-14 · NCT07794761 · CT.gov ↗
What to watch
Disitamab VedotinPhase 1/2High-risk Non-muscle Invasive Bladder Cancer
Est. primary completion 2029-03-15 · NCT06378242 · CT.gov ↗
What to watch
Est. primary completion 2029-03-27 · NCT05156398 · CT.gov ↗
What to watch
April 2029 (1)
abrocitinib · CibinqoPhase 3Atopic Dermatitis
Est. primary completion 2029-04-10 · NCT07823595 · CT.gov ↗
What to watch
June 2029 (7)
tilrekimigPhase 3Asthma
Est. primary completion 2029-06-01 · NCT07772921 · CT.gov ↗
What to watch
PF-08634404Phase 3Endometrial Neoplasms, Endometrial Cancer
Est. primary completion 2029-06-01 · NCT07578649 · CT.gov ↗
What to watch
tilrekimigPhase 3Asthma
Est. primary completion 2029-06-07 · NCT07869043 · CT.gov ↗
What to watch
etrasimod · VelsipityPhase 2Ulcerative Colitis
Est. primary completion 2029-06-16 · NCT05287126 · CT.gov ↗
What to watch
etrasimod · VelsipityPhase 3Ulcerative Colitis
Est. primary completion 2029-06-19 · NCT03950232 · CT.gov ↗
What to watch
Enfortumab VedotinPhase 1/2Locally Advanced or Metastatic Malignant Solid Tumors
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch
Disitamab VedotinPhase 3Gastric Carcinoma
Est. primary completion 2029-06-30 · NCT07315750 · CT.gov ↗
What to watch
July 2029 (1)
Tucatinib + Disitamab VedotinPhase 2Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms …
Est. primary completion 2029-07-28 · NCT06157892 · CT.gov ↗
What to watch
August 2029 (1)
Palbociclib · Ibrance + Prifetrastat + Vepdegestrant · Veppanu + AtirmociclibPhase 2Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer …
Est. primary completion 2029-08-27 · NCT04606446 · CT.gov ↗
What to watch
October 2029 (1)
AtirmociclibPhase 2Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Est. primary completion 2029-10-07 · NCT04557449 · CT.gov ↗
What to watch
November 2029 (1)
alprostadilPhase 3End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV
Est. primary completion 2029-11 · NCT00610051 · CT.gov ↗
What to watch
December 2029 (2)
Sugemalimab · CejemlyPhase 3Extranodal NK/T-cell Lymphoma
Est. primary completion 2029-12 · NCT05700448 · CT.gov ↗
What to watch
Palbociclib · IbrancePhase 2Breast Cancer, Head and Neck Cancer
Est. primary completion 2029-12-31 · NCT05226871 · CT.gov ↗
What to watch
2030 (12)
February 2030 (2)
PF-08634404Phase 3Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Digestive System Diseases …
Est. primary completion 2030-02-23 · NCT07222800 · CT.gov ↗
What to watch
Est. primary completion 2030-02-26 · NCT06616194 · CT.gov ↗
What to watch
March 2030 (2)
afimkibartPhase 3Moderately to Severely Active Ulcerative Colitis
Est. primary completion 2030-03-31 · NCT07158242 · CT.gov ↗
What to watch
Enfortumab VedotinPhase 3Urothelial Cancer, Urinary Bladder Neoplasms
Est. primary completion 2030-03-31 · NCT07566156 · CT.gov ↗
What to watch
May 2030 (1)
afimkibartPhase 3Moderately to Severely Active Crohns Disease
Est. primary completion 2030-05-31 · NCT07298421 · CT.gov ↗
What to watch
June 2030 (2)
PF-08634404Phase 2/3Small Cell Lung Cancer (SCLC)
Est. primary completion 2030-06-14 · NCT07226999 · CT.gov ↗
What to watch
PF-06651600Phase 3Severe Alopecia Areata
Est. primary completion 2030-06-26 · NCT07029828 · CT.gov ↗
What to watch
July 2030 (2)
PF-06823859Phase 3Myositis
Est. primary completion 2030-07-29 · NCT05895786 · CT.gov ↗
What to watch
Rimegepant (Nurtec ODT)Phase 3Acute Treatment of Migraine
Est. primary completion 2030-07-31 · NCT04743141 · CT.gov ↗
What to watch
September 2030 (1)
etrasimod · VelsipityPhase 2Colitis, Ulcerative
Est. primary completion 2030-09-08 · NCT07470879 · CT.gov ↗
What to watch
October 2030 (2)
ElranatamabPhase 3Multiple Myeloma
Est. primary completion 2030-10-18 · NCT05623020 · CT.gov ↗
What to watch
tilrekimigPhase 2/3Moderate to Severe Chronic Obstructive Pulmonary Disease
Est. primary completion 2030-10-24 · NCT07363694 · CT.gov ↗
What to watch
2031 (2)
July 2031 (2)
PF-08634404Phase 2/3Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer …
Est. primary completion 2031-07-22 · NCT07392892 · CT.gov ↗
What to watch
PF-06823859Phase 3Dermatomyositis, Polymyositis
Est. primary completion 2031-07-29 · NCT06698796 · CT.gov ↗
What to watch
2032 (3)
February 2032 (1)
abrocitinib · CibinqoPhase 3Atopic Dermatitis
Est. primary completion 2032-02-22 · NCT06807281 · CT.gov ↗
What to watch
April 2032 (1)
AtirmociclibPhase 3Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)
Est. primary completion 2032-04-13 · NCT07890597 · CT.gov ↗
What to watch
August 2032 (1)
TucatinibPhase 1/2Breast Neoplasms, Breast Cancer
Est. primary completion 2032-08-02 · NCT06686394 · CT.gov ↗
What to watch
2033 (2)
March 2033 (1)
afimkibartPhase 2Atopic Dermatitis
Est. primary completion 2033-03-01 · NCT07223697 · CT.gov ↗
What to watch
July 2033 (1)
afimkibartPhase 2Rheumatoid Arthritis
Est. primary completion 2033-07-08 · NCT07620392 · CT.gov ↗
What to watch
2034 (1)
April 2034 (1)
tilrekimigPhase 3Moderate to Severe Chronic Obstructive Pulmonary Disease
Est. primary completion 2034-04-21 · NCT07839884 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(42)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026ApprovaltofacitinibFDA updates Boxed Warning on Xeljanz (NDA203214)
US, FDA · FDA · Source ↗
1 May 2027FDA action dateAXS-12AXS-12 NDA PDUFA target action date
US, FDA · Axsome Therapeutics · Source ↗

Recent

27 October 2026Topline resultElranatamabMagnetisMM-32 Phase 3 meets its primary endpoint
Pfizer · Source ↗
26 October 2026ApprovalTalazoparibFDA approves Talzenna plus enzalutamide in an earlier prostate cancer setting
US, FDA · Pfizer · Source ↗
23 October 2026ApprovalEnfortumab VedotinEuropean Commission expands Padcev approval to resectable MIBC
EU, EC · Source ↗
21 October 2026Topline resultbrepocitinibPhase 3 CLARITY-1 and CLARITY-2 of brepocitinib in non-infectious uveitis met their primary endpoint (time to treatment failure)
Roivant Sciences and Priovant Therapeutics · Source ↗
7 October 2026ApprovalTucatinibFDA approves TUKYSA with trastuzumab and pertuzumab as first-line maintenance in HER2-positive metastatic breast cancer (HER2CLIMB-05)
US, FDA · Source ↗
October 2026ApprovalTucatinibFDA updates Boxed Warning on Tucatinib (NDA213411)
US, FDA · FDA · Source ↗
27 August 2026ApprovalbrepocitinibFDA approves LISRAYA (brepocitinib) for adults with dermatomyositis
US, FDA · Source ↗
27 August 2026ApprovalbrepocitinibFDA Boxed Warning on Lisraya (NDA220106)
US, FDA · FDA · Source ↗
17 August 2026FDA action dateEnfortumab VedotinPDUFA target action date August 17, 2026
US, FDA · Source ↗
31 July 2026WithdrawalVoxelotor (Oxbryta)Pfizer withdraws the Oxbryta NDAs
US, FDA · Source ↗
15 July 2026Filing acceptedAXS-12FDA accepts AXS-12 NDA
US, FDA · Axsome Therapeutics · Source ↗
7 July 2026Filing acceptedEnfortumab VedotinNMPA accepts BLA for Padcev plus Keytruda in muscle-invasive bladder cancer
CN, NMPA · Source ↗

The 12 most recent of 40 past events are shown.

Financial reports

Quarterly & interim (19)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$16.6B$3.0B$1.9B+ $9.1B short-term inv.—$5.4B operating cash flowreport ↗
View 18 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$15.0B$2.8B$1.0B+ $7.3B short-term inv.$248M$835M operating cash flowreport ↗
2026-Q1$14.5B$2.5B—+ $8.2B short-term inv.—$2.6B operating cash flowreport ↗
2025-Q4$17.6B$3.2B$13.6B—report ↗
2025-Q3$16.7B$2.5B$15.0B+ $10.1B short-term inv.—$4.6B operating cash flowreport ↗
2025-Q2$14.7B$2.5B$13.2B+ $9.5B short-term inv.—-$582M operating cash flowreport ↗
2025-Q1$13.7B$2.2B$17.3B+ $14.0B short-term inv.—$2.3B operating cash flowreport ↗
2024-Q4$17.8B$3.0B$20.5B—report ↗
2024-Q3$17.7B$2.6B$10.0B+ $6.8B short-term inv.—$6.7B operating cash flowreport ↗
2024-Q2$13.3B$2.7B$7.1B+ $4.4B short-term inv.—-$1.8B operating cash flowreport ↗
2024-Q1$14.9B$2.5B$780M+ $8.2B short-term inv.—$1.1B operating cash flowreport ↗
2023-Q4$13.2B$2.7B$3.2B+ $26.2B short-term inv.$2.4B$3.5B operating cash flowreport ↗
2023-Q3$12.7B$2.6B$2.7B+ $24.1B short-term inv.—-$1.2B operating cash flowreport ↗
2023-Q2$18.3B$2.5B$2.2B+ $16.1B short-term inv.—$1.2B operating cash flowreport ↗
2022-Q4$22.6B$2.7B$1.3B+ $20.2B short-term inv.—$6.0B operating cash flowreport ↗
2022-Q3$27.7B$2.8B$1.8B+ $25.6B short-term inv.—$8.2B operating cash flowreport ↗
2022-Q2$25.7B$2.3B$2.5B+ $17.3B short-term inv.—$6.5B operating cash flowreport ↗
2021-Q4—$3.4B$2.0B+ $27.7B short-term inv.—$10.8B operating cash flowreport ↗
2021-Q3—$2.5B$2.4B+ $19.3B short-term inv.—$11.3B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$62.6B$10.4B$13.6B+ $9.2B short-term inv.—$11.7B operating cash flowreport ↗

Pfizer reported full-year 2025 revenue of $62,579M, down 2% YoY, with R&D spend of $10,437M, down 4% YoY. Cash and equivalents were $13,596M, and net income was $7,771M, down 3% YoY.

The company reaffirmed full-year 2026 guidance, including revenues of $59.5–62.5 billion and adjusted diluted EPS of $2.80–3.00. Key developments included completion of the Metsera acquisition, a global GLP-1 collaboration with YaoPharma, and an agreement to exit its ViiV Healthcare stake for $1.875 billion. Clinical highlights featured positive Phase 3 results for Braftovi, Hympavzi, Padcev, and Tukysa, plus positive Phase 2b results for the ultra-long-acting GLP-1 candidate PF-3944; Pfizer plans approximately 20 key pivotal study starts in 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$63.6B$10.8B$20.5B+ $10.9B short-term inv.—$12.7B operating cash flowreport ↗
2023-FY$58.5B$10.7B$12.7B+ $4.4B short-term inv.—$8.7B operating cash flowreport ↗
2022-FY$100.3B$11.4B$468M+ $18.7B short-term inv.—$29.3B operating cash flowreport ↗
2021-FY$81.3B$13.8B$2.0B+ $22.0B short-term inv.—$32.6B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 3 purchases ($3.0M), 2 sales ($135K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13BOURLA ALBERT · director, Chairman & CEOAward / grant (derivative)21$28.89$607Form 4
2026-10-30BOURLA ALBERT · director, Chairman & CEOAward / grant (derivative)20$30.52$610Form 4
2026-10-15BOURLA ALBERT · director, Chairman & CEOAward / grant (derivative)20$29.44$589Form 4
2026-10-13BOURLA ALBERT · director, Chairman & CEOAward / grant (derivative)71$28.37$2KForm 4
2026-09-30BOURLA ALBERT · director, Chairman & CEOAward / grant (derivative)21$28.52$599Form 4
2026-09-25Taraporevala Cyrus · directorAward / grant (derivative)1,307.987$28.67$37KForm 4
2026-09-25SMITH JAMES C · directorAward / grant (derivative)1,569.585$28.67$45KForm 4
2026-09-25Quincey James · directorAward / grant (derivative)1,351.587$28.67$39KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2,912 reporting institutions held 3741.5M shares ($101.1B, 65.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.498,257,550$14.0B
2VANGUARD CAPITAL MANAGEMENT LLC369,430,012$10.4B
3STATE STREET CORP301,589,865$8.5B
4GEODE CAPITAL MANAGEMENT, LLC133,561,742$3.7B
5VANGUARD PORTFOLIO MANAGEMENT LLC116,734,695$3.3B
6Fisher Asset Management, LLC104,964,427$2.9B
7MORGAN STANLEY92,685,370$2.6B
8NORTHERN TRUST CORP62,026,552$1.7B
9MASSACHUSETTS FINANCIAL SERVICES CO /MA/56,911,830$1.6B
10STATE FARM MUTUAL AUTOMOBILE INSURANCE CO54,508,560$1.5B
11Bank of New York Mellon Corp53,879,900$1.5B
12CHARLES SCHWAB INVESTMENT MANAGEMENT INC51,891,636$1.5B
13WELLINGTON MANAGEMENT GROUP LLP49,916,961$1.4B
14GOLDMAN SACHS GROUP INC47,105,556$1.3B
15BANK OF AMERICA CORP /DE/46,545,479$1.3B